Key points are not available for this paper at this time.
“In the absence of randomized trial data in younger and middle-aged adults with low 10–30 year risk, the role of additional risk stratification tools—such as hsCRP and coronary artery calcium scoring—becomes critical in guiding individualized decisions about when to begin lipid-lowering pharmacoth...”
Ference et al. (Fri,) studied this question.